Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07245667 · ClinicalTrials.gov registry record · Phase 2
Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study
A Phase 2 study of Tinea Pedis, sponsored by Propedix.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT07245667: Recruiting Phase 2 study of Tinea Pedis, sponsored by Propedix.
NCT07245667 is a Phase 2 study of Tinea Pedis that is actively recruiting participants, run by Propedix. The registered enrollment target is 150 participants, below the 310-participant average among 9 other Tinea Pedis trials with a reported enrollment target (52% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07245667, a Phase 2 study of Tinea Pedis, is actively recruiting participants, sponsored by Propedix.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is designed to evaluate the safety and effectiveness of multiple 1% tolnaftate formulations delivered through novel stick-based vehicles in individuals with tinea pedis (athlete's foot).
Primary Outcome
Primary Efficacy Endpoint: Effective treatment, defined as mycological cure, based on a negative potassium hydroxide (KOH) test at week 4.
Conditions Studied
Interventions
- DRUG 1% Tolnaftate Stick Formula A
- DRUG 1% Tolnaftate Stick Formula B
- DRUG 1% Tolnaftate Stick Formula C
Study Locations (2)
Massachusetts
- Kuchnir Dermatology and Dermatological Surgery - Framingham
- Kuchnir Dermatology and Dermatological Surgery - Milford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2026-02 |
| Phase | Phase 2 |
What NCT07245667 shows while recruiting
NCT07245667 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 310-participant average among 9 other Tinea Pedis trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Tinea Pedis appearing as the primary indexed condition, and to 3 interventions - of which 1% Tolnaftate Stick Formula A is the first listed.
NCT07245667 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07245667 about?
NCT07245667 is a clinical study titled "Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study". This study is designed to evaluate the safety and effectiveness of multiple 1% tolnaftate formulations delivered through novel stick-based vehicles in individuals with tinea pedis (athlete's foot).
What is the current status of trial NCT07245667?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-12-30. Estimated completion is 2026-02.
What conditions does trial NCT07245667 study?
This clinical trial studies the following conditions: Tinea Pedis.
What interventions are being tested in trial NCT07245667?
The interventions under investigation include: 1% Tolnaftate Stick Formula A (DRUG), 1% Tolnaftate Stick Formula B (DRUG), 1% Tolnaftate Stick Formula C (DRUG).
Who is sponsoring clinical trial NCT07245667?
This trial is sponsored by Propedix, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07245667 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tinea Pedis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07245667's enrollment target sits among peer trials
150 6th of 9 higher than 4 of 9 other Tinea Pedis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tinea Pedis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Econazole Foam 1% in Athlete's Foot
COMPLETED · Phase 2
-
Three-Arm Trial of Novel Treatment for Tinea Pedis
COMPLETED · Phase 2
-
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
COMPLETED · Phase 1
-
Spread of Dermatophytes Among Families
COMPLETED
-
BE Study of Naftifine HCL
COMPLETED · Phase 3
-
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI